AR082054A1 - Derivados aril- y heteroarilamida como inhibidor de enzima pde10a - Google Patents
Derivados aril- y heteroarilamida como inhibidor de enzima pde10aInfo
- Publication number
- AR082054A1 AR082054A1 ARP110102334A ARP110102334A AR082054A1 AR 082054 A1 AR082054 A1 AR 082054A1 AR P110102334 A ARP110102334 A AR P110102334A AR P110102334 A ARP110102334 A AR P110102334A AR 082054 A1 AR082054 A1 AR 082054A1
- Authority
- AR
- Argentina
- Prior art keywords
- heteroarilamide
- aril
- derivatives
- butyl
- attachment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Y su uso como ingredientes farmacéuticos, en particular para el tratamiento de enfermedades relacionadas con el SNC.Reivindicación 1: El compuesto de fórmula (1) donde het1 se selecciona del grupo de fórmulas (2) y donde * indica el punto de unión, y het2 se selecciona del grupo de fórmulas (3) y donde * indica el punto de unión, y donde además L es un enlace seleccionado del compuesto de fórmula (4) ó (5) y donde R1 se selecciona del grupo compuesto por alquilo C1-6 tal como metilo, etilo, 1-propilo, 2-propilo, isobutilo, n-butilo, sec-butilo o ter-butilo; alquil C1-6, cicloalquilo C3-8 tal como ciclopropilmetilo, y donde * indica el punto de unión; así como también tautómeros y sales de adición ácidas aceptables farmacéuticamente de las mismas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201000584 | 2010-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR082054A1 true AR082054A1 (es) | 2012-11-07 |
Family
ID=44314221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110102334A AR082054A1 (es) | 2010-07-02 | 2011-06-30 | Derivados aril- y heteroarilamida como inhibidor de enzima pde10a |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR082054A1 (es) |
TW (1) | TW201215607A (es) |
WO (1) | WO2012000519A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2675791B1 (en) | 2011-02-18 | 2016-02-17 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE58870B1 (en) | 1985-03-08 | 1993-11-17 | Leo Pharm Prod Ltd | Pyridine derivatives |
IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
EP1641457B1 (en) | 2003-06-30 | 2009-08-05 | Nycomed GmbH | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
US20060148838A1 (en) | 2003-06-30 | 2006-07-06 | Altana Pharma Ag | Novel pyrrolodihydroisoquinolines useful in the treatment of cancer |
US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
EP1723134A2 (en) | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
MXPA06014236A (es) | 2004-06-07 | 2007-02-14 | Pfizer Prod Inc | Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad. |
US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
WO2006028957A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
AU2006223508A1 (en) * | 2005-03-09 | 2006-09-21 | Merck Frosst Canada Ltd | Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use |
NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
TW200918519A (en) * | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物 |
-
2011
- 2011-06-28 TW TW100122538A patent/TW201215607A/zh unknown
- 2011-06-30 AR ARP110102334A patent/AR082054A1/es unknown
- 2011-07-01 WO PCT/DK2011/050257 patent/WO2012000519A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2012000519A1 (en) | 2012-01-05 |
TW201215607A (en) | 2012-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
ECSP18018453A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico | |
UY33694A (es) | ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?. | |
NI201200061A (es) | Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3 | |
MX336381B (es) | Boronatos como inhibidores de arginasa. | |
CL2014000630A1 (es) | Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc. | |
BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
CO6541645A2 (es) | Compuestos de indol y su uso farmaceutico | |
CR20120190A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
UY32648A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades | |
BR112013023876A2 (pt) | derivados de pirroltriazinona como inibidores de pi3k | |
NI201500134A (es) | Derivados de 2-((4-amino-3-(3-flúor-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il) metil)-3-(2-(trifluorometil)bencil)quinazolina-4(3h)-ona y su uso como inhibidores de fosfoinositida 3-quinasas | |
EA201201663A1 (ru) | Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1 | |
UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
NI201300111A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
EA201390198A1 (ru) | Гетероциклическое соединение | |
MY183312A (en) | Pharmaceutical formulation | |
BR112014006559A2 (pt) | derivados do ácido betulínico com atividade antiviral | |
PE20142450A1 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
EA201190234A1 (ru) | Новые амидные производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью | |
CU20120081A7 (es) | Nuevas formas polimorfas de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo | |
ECSP13012548A (es) | Inhibidores de oxadiazol de la producción de leucotrienos. | |
BR112012009311A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
AR082054A1 (es) | Derivados aril- y heteroarilamida como inhibidor de enzima pde10a | |
AR082230A1 (es) | Derivados de triazolo- y pirazoloquinazolina como inhibidor de la enzima pde10a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |